AZ Brushes Off Vaccine Criticism, Awaits US Readout
WHO Endorsement Counters Fears
Executive Summary
While fast-developing news on COVID-19 is grabbing the headlines, oncology will continue to drive growth in 2021.
You may also be interested in...
After COVID-19 Vaccine Setbacks, GSK Expands Vir Antibody Pact
The agreement focuses on respiratory viruses, especially influenza, and includes a $225m upfront payment plus an increase in GSK’s equity investment in Vir.
AZ's Alexion Acquisition Looks Astute Bit Of Business
Some analysts are suggesting that AstraZeneca is getting hold of a "scarce and high-quality asset" in Alexion for a very reasonable price and shareholders could demand more than the $175 per share offer on the table.
Novartis’s Latecomer PD-1 Outshines Keytruda And Opdivo In Esophageal Cancer
Novartis is playing catch-up in PD-1 inhibitors but could soon claim a best-in-class competitor in first-line esophageal cancer.